Loading…
CDK4/6 inhibitors: The Devil is in the Detail
Purpose of review Update on the most recent clinical evidence on CDK4/6 inhibitors (CDK4/6i) in the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor (HER)2-negative breast cancer. Recent findings Over the past decade, CDK4/6i have become part of the standard of car...
Saved in:
| Published in: | Current oncology reports 2024-06, Vol.26 (6), p.665-678 |
|---|---|
| Main Authors: | , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c375t-78f44a3c2abe1c80496d6b5a463735a5c8e15361d9fce74dc68aae6713ccc7b13 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c375t-78f44a3c2abe1c80496d6b5a463735a5c8e15361d9fce74dc68aae6713ccc7b13 |
| container_end_page | 678 |
| container_issue | 6 |
| container_start_page | 665 |
| container_title | Current oncology reports |
| container_volume | 26 |
| creator | Magge, Tara Rajendran, Sneha Brufsky, Adam M. Foldi, Julia |
| description | Purpose of review
Update on the most recent clinical evidence on CDK4/6 inhibitors (CDK4/6i) in the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor (HER)2-negative breast cancer.
Recent findings
Over the past decade, CDK4/6i have become part of the standard of care treatment of patients with both metastatic and high-risk early HR + /HER2- breast cancers. The three available CDK4/6i (palbociclib, ribociclib and abemaciclib) have been extensively studied in combination with endocrine therapy (ET) in metastatic breast cancer (mBC) with consistent prolongation of progression free survival; however, ribociclib has emerged as the preferred first line agent in mBC given overall survival benefit over endocrine monotherapy. In early BC, abemaciclib is the only currently approved agent while ribociclib has early positive clinical trial data. Toxicities and financial burden limit the use of CDK4/6i in all patients and resource-poor settings, and optimal timing of their use in mBC remains unclear.
Summary
There is considerable evidence for the use of CDK4/6i in metastatic and early HR + /HER2- breast cancer, but knowledge gaps remain, and further research is necessary to better define their optimal use. |
| doi_str_mv | 10.1007/s11912-024-01540-7 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3051939091</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3051939091</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-78f44a3c2abe1c80496d6b5a463735a5c8e15361d9fce74dc68aae6713ccc7b13</originalsourceid><addsrcrecordid>eNp9kDtPwzAYRS0EoqXwBxhQJBYWU7-dsKGWl6jEUmbLcRzqKk2KnSDx73GaAhIDk21957u-OgCcY3SNEZLTgHGGCUSEQYQ5Q1AegDHmlEFBRHbY3wmFVGZoBE5CWCNEEErRMRjRVGJKMR4DOJs_s6lIXL1yuWsbH26S5comc_vhqsSFOEja3bvVrjoFR6Wugj3bnxPwen-3nD3CxcvD0-x2AQ2VvIUyLRnT1BCdW2xSxDJRiJxrJqikXHOT2lhT4CIrjZWsMCLV2orYyRgjc0wn4GrI3frmvbOhVRsXjK0qXdumC4oijjOaoaxHL_-g66bzdWwXqRiJGScyUmSgjG9C8LZUW-822n8qjFQvUw0yVZSpdjJVv3Sxj-7yjS1-Vr7tRYAOQIij-s3637__if0CyAx7WQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3067114527</pqid></control><display><type>article</type><title>CDK4/6 inhibitors: The Devil is in the Detail</title><source>Springer Nature</source><creator>Magge, Tara ; Rajendran, Sneha ; Brufsky, Adam M. ; Foldi, Julia</creator><creatorcontrib>Magge, Tara ; Rajendran, Sneha ; Brufsky, Adam M. ; Foldi, Julia</creatorcontrib><description>Purpose of review
Update on the most recent clinical evidence on CDK4/6 inhibitors (CDK4/6i) in the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor (HER)2-negative breast cancer.
Recent findings
Over the past decade, CDK4/6i have become part of the standard of care treatment of patients with both metastatic and high-risk early HR + /HER2- breast cancers. The three available CDK4/6i (palbociclib, ribociclib and abemaciclib) have been extensively studied in combination with endocrine therapy (ET) in metastatic breast cancer (mBC) with consistent prolongation of progression free survival; however, ribociclib has emerged as the preferred first line agent in mBC given overall survival benefit over endocrine monotherapy. In early BC, abemaciclib is the only currently approved agent while ribociclib has early positive clinical trial data. Toxicities and financial burden limit the use of CDK4/6i in all patients and resource-poor settings, and optimal timing of their use in mBC remains unclear.
Summary
There is considerable evidence for the use of CDK4/6i in metastatic and early HR + /HER2- breast cancer, but knowledge gaps remain, and further research is necessary to better define their optimal use.</description><identifier>ISSN: 1523-3790</identifier><identifier>ISSN: 1534-6269</identifier><identifier>EISSN: 1534-6269</identifier><identifier>DOI: 10.1007/s11912-024-01540-7</identifier><identifier>PMID: 38713311</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Aminopyridines - therapeutic use ; Benzimidazoles ; Breast cancer ; Breast Neoplasms - drug therapy ; Breast Neoplasms - pathology ; Cyclin-dependent kinase 4 ; Cyclin-Dependent Kinase 4 - antagonists & inhibitors ; Cyclin-Dependent Kinase 6 - antagonists & inhibitors ; Endocrine therapy ; ErbB-2 protein ; Female ; Humans ; Medicine ; Medicine & Public Health ; Metastases ; Metastasis ; Oncology ; Patients ; Protein Kinase Inhibitors - therapeutic use ; Purines - pharmacology ; Purines - therapeutic use ; Review ; Survival ; Topical Collection on Breast Cancer</subject><ispartof>Current oncology reports, 2024-06, Vol.26 (6), p.665-678</ispartof><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-78f44a3c2abe1c80496d6b5a463735a5c8e15361d9fce74dc68aae6713ccc7b13</citedby><cites>FETCH-LOGICAL-c375t-78f44a3c2abe1c80496d6b5a463735a5c8e15361d9fce74dc68aae6713ccc7b13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38713311$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Magge, Tara</creatorcontrib><creatorcontrib>Rajendran, Sneha</creatorcontrib><creatorcontrib>Brufsky, Adam M.</creatorcontrib><creatorcontrib>Foldi, Julia</creatorcontrib><title>CDK4/6 inhibitors: The Devil is in the Detail</title><title>Current oncology reports</title><addtitle>Curr Oncol Rep</addtitle><addtitle>Curr Oncol Rep</addtitle><description>Purpose of review
Update on the most recent clinical evidence on CDK4/6 inhibitors (CDK4/6i) in the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor (HER)2-negative breast cancer.
Recent findings
Over the past decade, CDK4/6i have become part of the standard of care treatment of patients with both metastatic and high-risk early HR + /HER2- breast cancers. The three available CDK4/6i (palbociclib, ribociclib and abemaciclib) have been extensively studied in combination with endocrine therapy (ET) in metastatic breast cancer (mBC) with consistent prolongation of progression free survival; however, ribociclib has emerged as the preferred first line agent in mBC given overall survival benefit over endocrine monotherapy. In early BC, abemaciclib is the only currently approved agent while ribociclib has early positive clinical trial data. Toxicities and financial burden limit the use of CDK4/6i in all patients and resource-poor settings, and optimal timing of their use in mBC remains unclear.
Summary
There is considerable evidence for the use of CDK4/6i in metastatic and early HR + /HER2- breast cancer, but knowledge gaps remain, and further research is necessary to better define their optimal use.</description><subject>Aminopyridines - therapeutic use</subject><subject>Benzimidazoles</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - pathology</subject><subject>Cyclin-dependent kinase 4</subject><subject>Cyclin-Dependent Kinase 4 - antagonists & inhibitors</subject><subject>Cyclin-Dependent Kinase 6 - antagonists & inhibitors</subject><subject>Endocrine therapy</subject><subject>ErbB-2 protein</subject><subject>Female</subject><subject>Humans</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Oncology</subject><subject>Patients</subject><subject>Protein Kinase Inhibitors - therapeutic use</subject><subject>Purines - pharmacology</subject><subject>Purines - therapeutic use</subject><subject>Review</subject><subject>Survival</subject><subject>Topical Collection on Breast Cancer</subject><issn>1523-3790</issn><issn>1534-6269</issn><issn>1534-6269</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9kDtPwzAYRS0EoqXwBxhQJBYWU7-dsKGWl6jEUmbLcRzqKk2KnSDx73GaAhIDk21957u-OgCcY3SNEZLTgHGGCUSEQYQ5Q1AegDHmlEFBRHbY3wmFVGZoBE5CWCNEEErRMRjRVGJKMR4DOJs_s6lIXL1yuWsbH26S5comc_vhqsSFOEja3bvVrjoFR6Wugj3bnxPwen-3nD3CxcvD0-x2AQ2VvIUyLRnT1BCdW2xSxDJRiJxrJqikXHOT2lhT4CIrjZWsMCLV2orYyRgjc0wn4GrI3frmvbOhVRsXjK0qXdumC4oijjOaoaxHL_-g66bzdWwXqRiJGScyUmSgjG9C8LZUW-822n8qjFQvUw0yVZSpdjJVv3Sxj-7yjS1-Vr7tRYAOQIij-s3637__if0CyAx7WQ</recordid><startdate>20240601</startdate><enddate>20240601</enddate><creator>Magge, Tara</creator><creator>Rajendran, Sneha</creator><creator>Brufsky, Adam M.</creator><creator>Foldi, Julia</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>20240601</creationdate><title>CDK4/6 inhibitors: The Devil is in the Detail</title><author>Magge, Tara ; Rajendran, Sneha ; Brufsky, Adam M. ; Foldi, Julia</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-78f44a3c2abe1c80496d6b5a463735a5c8e15361d9fce74dc68aae6713ccc7b13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Aminopyridines - therapeutic use</topic><topic>Benzimidazoles</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - pathology</topic><topic>Cyclin-dependent kinase 4</topic><topic>Cyclin-Dependent Kinase 4 - antagonists & inhibitors</topic><topic>Cyclin-Dependent Kinase 6 - antagonists & inhibitors</topic><topic>Endocrine therapy</topic><topic>ErbB-2 protein</topic><topic>Female</topic><topic>Humans</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Oncology</topic><topic>Patients</topic><topic>Protein Kinase Inhibitors - therapeutic use</topic><topic>Purines - pharmacology</topic><topic>Purines - therapeutic use</topic><topic>Review</topic><topic>Survival</topic><topic>Topical Collection on Breast Cancer</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Magge, Tara</creatorcontrib><creatorcontrib>Rajendran, Sneha</creatorcontrib><creatorcontrib>Brufsky, Adam M.</creatorcontrib><creatorcontrib>Foldi, Julia</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Current oncology reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Magge, Tara</au><au>Rajendran, Sneha</au><au>Brufsky, Adam M.</au><au>Foldi, Julia</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CDK4/6 inhibitors: The Devil is in the Detail</atitle><jtitle>Current oncology reports</jtitle><stitle>Curr Oncol Rep</stitle><addtitle>Curr Oncol Rep</addtitle><date>2024-06-01</date><risdate>2024</risdate><volume>26</volume><issue>6</issue><spage>665</spage><epage>678</epage><pages>665-678</pages><issn>1523-3790</issn><issn>1534-6269</issn><eissn>1534-6269</eissn><abstract>Purpose of review
Update on the most recent clinical evidence on CDK4/6 inhibitors (CDK4/6i) in the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor (HER)2-negative breast cancer.
Recent findings
Over the past decade, CDK4/6i have become part of the standard of care treatment of patients with both metastatic and high-risk early HR + /HER2- breast cancers. The three available CDK4/6i (palbociclib, ribociclib and abemaciclib) have been extensively studied in combination with endocrine therapy (ET) in metastatic breast cancer (mBC) with consistent prolongation of progression free survival; however, ribociclib has emerged as the preferred first line agent in mBC given overall survival benefit over endocrine monotherapy. In early BC, abemaciclib is the only currently approved agent while ribociclib has early positive clinical trial data. Toxicities and financial burden limit the use of CDK4/6i in all patients and resource-poor settings, and optimal timing of their use in mBC remains unclear.
Summary
There is considerable evidence for the use of CDK4/6i in metastatic and early HR + /HER2- breast cancer, but knowledge gaps remain, and further research is necessary to better define their optimal use.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>38713311</pmid><doi>10.1007/s11912-024-01540-7</doi><tpages>14</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1523-3790 |
| ispartof | Current oncology reports, 2024-06, Vol.26 (6), p.665-678 |
| issn | 1523-3790 1534-6269 1534-6269 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3051939091 |
| source | Springer Nature |
| subjects | Aminopyridines - therapeutic use Benzimidazoles Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - pathology Cyclin-dependent kinase 4 Cyclin-Dependent Kinase 4 - antagonists & inhibitors Cyclin-Dependent Kinase 6 - antagonists & inhibitors Endocrine therapy ErbB-2 protein Female Humans Medicine Medicine & Public Health Metastases Metastasis Oncology Patients Protein Kinase Inhibitors - therapeutic use Purines - pharmacology Purines - therapeutic use Review Survival Topical Collection on Breast Cancer |
| title | CDK4/6 inhibitors: The Devil is in the Detail |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T21%3A48%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CDK4/6%20inhibitors:%20The%20Devil%20is%20in%20the%20Detail&rft.jtitle=Current%20oncology%20reports&rft.au=Magge,%20Tara&rft.date=2024-06-01&rft.volume=26&rft.issue=6&rft.spage=665&rft.epage=678&rft.pages=665-678&rft.issn=1523-3790&rft.eissn=1534-6269&rft_id=info:doi/10.1007/s11912-024-01540-7&rft_dat=%3Cproquest_cross%3E3051939091%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c375t-78f44a3c2abe1c80496d6b5a463735a5c8e15361d9fce74dc68aae6713ccc7b13%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3067114527&rft_id=info:pmid/38713311&rfr_iscdi=true |